La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Inovio Pharmaceuticals a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Inovio Pharmaceuticals..

Inovio Pharmaceuticals (NASDAQ:INO) Azioni, Catena delle Opzioni

Inovio Pharmaceuticals

Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

OTLK

RCKT

Strategie per individuare titoli con potenziale di crescita basate su indicatori RSI e tendenze di mercato.

Opportunità di investimento: 3 aziende sottovalutate nel settore sanitario

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals Inc

Innodata Inc

IN OVATIONS HOLDINGS INC by In Ovations Holdings, Inc.

In Ovations Holdings Inc

TPT Strategic Inc

Predictiv AI Inc

Innovator ETFs Trust Innovator International Developed Power Buffer ETF November

InfoNow Corp

WIIM

ACVA

AXON

CTAS

EOSE

FRGT

FTAI

GTLS

JBLU

MNTS

PAYC

PCTY

RAIL

SATL

WLFC

Shares of industrial stocks are trading lower following greater-than-expected inflation data measured through the PCE price index for February, while personal spending missed estimates. Additionally, recent tariff announcements may be weighing on equities.

RBC Capital analyst Gregory Renza maintains Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) with a Sector Perform and lowers the price target from $6 to $5.

Price Target

Analyst Ratings

RBC Capital Maintains Sector Perform on Inovio Pharmaceuticals, Lowers Price Target to $5

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) with a Neutral and maintains $3 price target.

Reiteration

HC Wainwright & Co. Reiterates Neutral on Inovio Pharmaceuticals, Maintains $3 Price Target

Earnings

Earnings Beats

Inovio Pharmaceuticals Q4 2024 GAAP EPS $(0.65) Beats $(0.90) Estimate, Sales $117.000K Beat $30.000K Estimate

<h3>Companies Reporting Before The Bell</h3>
• Bitcoin Depot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTM#NASDAQ">BTM</a>) is likely to report quarterly loss at $0.01 per share on revenue of $131.50 million. 
• United Maritime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEA#NASDAQ">USEA</a>) is expected to report quarterly loss at $0.41 per share on revenue of $9.50 million. 
• Flowco Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLOC#NYSE">FLOC</a>) is estimated to report quarterly earnings at $0.35 per share on revenue of $185.00 million. 
• Eton Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETON#NASDAQ">ETON</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $10.68 million. 
• MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) is expected to report earnings for its fourth quarter. 
• Citi Trends (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTRN#NASDAQ">CTRN</a>) is likely to report quarterly earnings at $0.18 per share on revenue of $211.54 million. 
• McEwen Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUX#NYSE">MUX</a>) is projected to report earnings for its fourth quarter. 
• ZKH Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZKH#NYSE">ZKH</a>) is estimated to report earnings for its fourth quarter. 
• HUYA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUYA#NYSE">HUYA</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $215.25 million. 
• XPeng (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) is projected to report earnings for its fourth quarter. 
• UP Fintech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NASDAQ">TIGR</a>) is expected to report earnings for its fourth quarter. 
• KE Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) is expected to report quarterly earnings at $0.26 per share on revenue of $4.01 billion. 
• Tencent Music Enter Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TME#NYSE">TME</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $1.01 billion. 
• Bakkt Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>) is likely to report earnings for its fourth quarter. 
• OneConnect Financial Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OCFT#NYSE">OCFT</a>) is likely to report earnings for its fourth quarter. 
• IHS Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $413.76 million. 
• Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) is projected to report earnings for its fourth quarter. 
• Elbit Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLT#NASDAQ">ESLT</a>) is estimated to report quarterly earnings at $1.95 per share on revenue of $1.78 billion. 
• SNDL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) is expected to report earnings for its fourth quarter. 
• NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) is projected to report earnings for its fourth quarter. 
<h3>Companies Reporting After The Bell</h3>
• ZTO Express (Cayman) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTO#NYSE">ZTO</a>) is likely to report quarterly earnings at $0.46 per share on revenue of $1.66 billion. 
• Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) is estimated to report quarterly loss at $0.93 per share on revenue of $30 thousand. 
• Trevi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>) is projected to report earnings for its fourth quarter. 
• LexinFintech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) is estimated to report earnings for its fourth quarter. 
• Better Home &amp; Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BETR#NASDAQ">BETR</a>) is likely to report earnings for its fourth quarter. 
• Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) is projected to report quarterly loss at $1.19 per share on revenue of $26.90 million. 
• Aterian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>) is estimated to report quarterly loss at $0.63 per share on revenue of $23.69 million. 
• Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) is likely to report quarterly loss at $0.21 per share on revenue of $1.82 million. 
• OmniAb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OABI#NASDAQ">OABI</a>) is likely to report quarterly loss at $0.10 per share on revenue of $10.13 million. 
• HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) is estimated to report quarterly earnings at $0.72 per share on revenue of $305.07 million. 
• StoneCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) is projected to report quarterly earnings at $0.35 per share on revenue of $647.56 million. 
• Waldencast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WALD#NASDAQ">WALD</a>) is likely to report quarterly loss at $0.25 per share on revenue of $272.22 million. 
• Orla Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ORLA#AMEX">ORLA</a>) is likely to report earnings for its fourth quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABSI

ACXP

ATER

BEKE

BETR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

CTRN

ESLT

ETON

FLOC

HUYA

INKT

OABI

OCFT

ORLA

SNDL

SRFM

STNE

TIGR

TRVI

USEA

WALD

XPEV

Earnings Scheduled For March 18, 2025

Citizens Capital Markets analyst Roy Buchanan reiterates Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) with a Market Outperform and maintains $18 price target.

Citizens Capital Markets Reiterates Market Outperform on Inovio Pharmaceuticals, Maintains $18 Price Target

<ul>
<li>Long-lasting in&nbsp;vivo antibody production: DMAb levels remained stable for 72 weeks in all participants (n=24) who have reached that timepoint</li>
<li>No anti-drug antibodies (ADA): no immune rejection of the&nbsp;DMAbs was detected across ~1,000 blood samples, unlike other gene-based antibody delivery approaches where ADA formation has been a challenge</li>
<li>Well-tolerated: most common side effects were mild, temporary injection site reactions such as pain and redness; no serious adverse events (SAEs) related to study drug</li>
<li>Effective target binding: expressed&nbsp;DMAbs successfully bound to the SARS-CoV-2 Spike protein receptor-binding domain (RBD), confirming functional activity through week 72</li>
</ul>

Reported Earlier, INOVIO Announces 72-Week Data From COVID-19 DNA Antibody Trial With No Serious Adverse Events Or Immune Reactions

Biotech

General

INOVIO Announces Phase 1/2 Trial Results Of INO-3107 For Recurrent Respiratory Papillomatosis With 81% Of Patients Requiring Fewer Surgeries; Plans BLA Submission In Mid-2025 For FDA Accelerated Approval, Aiming To Achieve First US DNA Medicine Approval

Inovio Announces That An Abstract Describing The Immunological Activity Of INO-3107 Will Be Presented As A Poster At The American Association For Cancer Research

<a href="https://www.manchestereveningnews.co.uk/news/health/new-case-mpox-detected-uk-30876004">https://www.manchestereveningnews.co.uk/news/health/new-case-mpox-detected-uk-30876004</a>
&nbsp;
A new case of Mpox has been confirmed in the UK, the UK Health Security Agency (UKHSA) has said.
The latest case of Clade Ib Mpox is the seventh confirmed case since October 2024 after a sixth patient <a href="https://www.manchestereveningnews.co.uk/news/uk-news/new-mpox-case-detected-uk-30823540">was admitted to hospital last week</a>.
<a href="https://www.gov.uk/government/news/ukhsa-detects-first-case-of-clade-ib-mpox?utm_medium=email&amp;utm_campaign=govuk-notifications-topic&amp;utm_source=d72f8bd1-0516-4336-9e7d-b4f8a791ba9a&amp;utm_content=immediately">The UKHSA says</a> the infected patient had recently travelled to Uganda and that the risk to the UK population "remains low". The UKHSA and <a href="https://www.manchestereveningnews.co.uk/all-about/nhs">NHS</a> says it will not be disclosing any further details about the infected person.
Professor Susan Hopkins, Chief Medical Adviser at UKHSA, said: "The risk to the UK population remains low. Close contacts have been identified and offered appropriate advice in order to reduce the chance of further spread."
Mpox, previously known as monkeypox, is a rare infection most commonly found in parts of central and east Africa.
There is currently community transmission of the virus in Uganda, which has so far recorded <a href="https://www.afro.who.int/countries/uganda/publication/mpox-outbreak-uganda-situation-update-22-january-2025">2,209 confirmed Mpox cases</a> and 13 deaths since July 2024.
The Clade Ib variant is a new form of the virus, the which the World Health Organisation (WHO) declared as a global health emergency in August.
WHO says common symptoms of Mpox include a skin rash or lesions which can last two to four weeks, as well as a fever, headache, muscle aches, back pain, low energy and swollen lymph nodes.
<a href="https://www.nhs.uk/conditions/mpox/">The NHS says</a> Mpox can be passed on from person to person through:
Close physical contact with Mpox blisters or scabs
Touching clothing, bedding or towels used by someone with Mpox
The coughs or sneezes of a person with Mpox when they're close to you

AEMD

APDN

CMRX

GOVX

MRNA

TNXP

VRAX

"New Case Of Mpox Detected In The UK After 'Concerning' Surge In Cases In Uganda" - Manchester Evening News

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) with a Neutral and lowers the price target from $5 to $3.

HC Wainwright & Co. Maintains Neutral on Inovio Pharmaceuticals, Lowers Price Target to $3

JMP Securities analyst Roy Buchanan reiterates Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) with a Market Outperform and maintains $18 price target.

JMP Securities Reiterates Market Outperform on Inovio Pharmaceuticals, Maintains $18 Price Target

Shares of Inovio Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) pulled back by 5.3% to $2.16 during Wednesday's session, following a <a href="https://www.benzinga.com/news/25/01/42857690/why-inovio-pharmaceuticals-ino-stock-is-skyrocketing">strong rally</a> Tuesday.
The decline may be attributed to profit-taking, as investors assess renewed focus on respiratory illnesses, with increased cases of influenza, COVID-19 and RSV <a href="https://www.benzinga.com/general/biotech/25/01/42854890/us-records-first-human-bird-flu-death-high-levels-of-respiratory-illnesses-vaccine-stocks-rally">driving interest</a> in vaccine developers.
What Else: Inovio's lead candidate, INO-4800, a DNA-based COVID-19 vaccine, remains a key focus among vaccine-makers, particularly as alternative vaccine technologies gain traction. The company is also advancing its broader pipeline, which includes vaccines for RSV, MERS and other pathogens.
While Wednesday's profit-taking reflects typical market volatility following a sharp rise, Inovio's long-term prospects remain tied to its ability to advance its portfolio and demonstrate the effectiveness of its DNA-based vaccine platform in addressing global health challenges.
Read Also: <a href="https://www.benzinga.com/25/01/42878295/quantum-stocks-tumble-why-rigetti-ionq-and-d-wave-are-falling">Quantum Stocks Tumble: Why Rigetti, IonQ and D-Wave Are Falling</a>
<h2 class="wp-block-heading">How To Buy INO Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Inovio Pharmaceuticals&#8217; case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, INO has a 52-week high of $14.75 and a 52-week low of $1.74.

What's Going On With Inovio Pharmaceuticals (INO) Stock?

Inovio Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) shares are trading higher by 17.9% to $2.27 Tuesday afternoon amid growing concerns about <a href="https://www.cdc.gov/respiratory-viruses/data/index.html#cdc_data_surveillance_section_2-weekly-national-summary">respiratory illnesses</a>, including seasonal influenza, COVID-19 and RSV. Increased attention to vaccine and therapeutic solutions this week has increased interest in biotechnology stocks focused on infectious diseases.
The Louisiana Department of Health also <a href="https://www.ldh.la.gov/news/H5N1-death">reported</a> the first U.S. H5N1 death, a patient over 65 with underlying conditions who contracted the virus from birds, with no further cases or person-to-person spread. This may increase demand for avian flu vaccines and research.
Read Also: <a href="https://www.benzinga.com/general/biotech/25/01/42854890/us-records-first-human-bird-flu-death-high-levels-of-respiratory-illnesses-vaccine-stocks-rally">US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally</a>
What Else: Inovio is known for its DNA-based vaccine technology platform. The company's lead product candidate, INO-4800, a DNA-based COVID-19 vaccine, remains a focal point of its pipeline, particularly for markets seeking alternatives to traditional mRNA vaccines.
Inovio's portfolio extends beyond COVID-19. The company is advancing research on vaccines targeting a variety of infectious diseases and cancers, with recent progress in its RSV and MERS vaccine programs. 
Additionally, its SynCon platform, which underpins its DNA medicines, enables the design and production of new vaccine candidates, potentially positioning Inovio as a player in responding to emerging global health threats.
Read Also: <a href="https://www.benzinga.com/news/25/01/42851023/why-novavax-nvax-stock-is-rising">Why Novavax Stock Is Rising</a>
<h2 class="wp-block-heading">How To Buy INO Stock</h2>
By now you're likely curious about how to participate in the market for Inovio Pharmaceuticals &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
In the case of Inovio Pharmaceuticals, which is trading at $2.33 as of publishing time, $100 would buy you 42.92 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.

Why Inovio Pharmaceuticals (INO) Stock Is Skyrocketing

BNTX

CVAC

NVAX

Shares of vaccine makers are trading higher after the first bird flu death was reporting in the US. Additionally, a recent CDC report noted an increase in acute respiratory illness activity.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Rocket Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>)</h3>
<ul>
<li>On Dec. 11, Rocket Pharmaceuticals announced a $165 million upsized public offering of 13.2 million shares at $12.50 per share. The company's stock fell around 10% over the past month and has a <a href="https://www.benzinga.com/quote/RCKT">52-week low of $11.15</a>.</li>
<li>RSI Value: 26.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>RCKT Price Action: Shares of Rocket Pharmaceuticals fell 1.3% to close at $12.56 on Friday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010625&amp;t=be2bearmibe3na1">latest RCKT news</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010625&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="893" height="843" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071723/image-18.png" alt="" class="wp-image-719464" style="width:556px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071723/image-18.png 893w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071723/image-18-300x283.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071723/image-18-768x725.png 768w" sizes="(max-width: 893px) 100vw, 893px" /></a></figure>
<h3 class="wp-block-heading">Inovio Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Dec. 13, Inovio Pharmaceuticals announced a public offering of 10 million shares for gross proceeds of $30 million.. The company's stock fell around 53% over the past month and <a href="https://www.benzinga.com/quote/INO">has a 52-week low</a> of $1.74.</li>
<li>RSI Value: 18.5</li>
<li>INO Price Action: Shares of Inovio Pharmaceuticals gained 7.7% to close at $1.96 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010625&amp;t=be2bearmibe3na1">trend in INO stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010625&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="923" height="848" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071810/image-19.png" alt="" class="wp-image-719466" style="width:677px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071810/image-19.png 923w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071810/image-19-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071810/image-19-768x706.png 768w" sizes="(max-width: 923px) 100vw, 923px" /></a></figure>
<h3 class="wp-block-heading">Outlook Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>)</h3>
<ul>
<li>On Dec. 27, Outlook Therapeutics announced a year-over-year increase in FY24 EPS results. &#8220;Over the course of the past year, our team has continued to execute and progress the development of ONS-5010/LYTENAVA&#x2122; in Europe and the United States. Following the receipt of our first positive reimbursement decision worldwide for LYTENAVA&#x2122; from NICE in the United Kingdom, our team continues to make preparations for commercial launch in the UK and Germany, which is expected in the first half of calendar 2025,&#8221; commented Lawrence Kenyon, Chief Financial Officer and Interim Chief Executive Officer of Outlook Therapeutics. The company's stock fell around 72% over the past six months and has a 52-week <a href="https://www.benzinga.com/quote/OTLK">low of $0.87</a>.</li>
<li>RSI Value: 26.9</li>
<li>OTLK Price Action: Shares of Outlook Therapeutics gained 8.8% to close at $2.24 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010625&amp;t=be2bearmibe3na1">breakout in OTLK shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010625&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="917" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071849/image-20.png" alt="" class="wp-image-719469" style="width:612px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071849/image-20.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071849/image-20-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071849/image-20-768x701.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/42791037/delta-air-lines-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Delta Air Lines Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>

Top 3 Health Care Stocks That Could Blast Off This Month

<h3>Gainers</h3>
<ul>
<li>Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) stock moved upwards by 18.7% to $4.31 during Friday's pre-market session. The market value of their outstanding shares is at $46.4 million. </li>
<li>Senseonics Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SENS#AMEX">SENS</a>) shares rose 16.0% to $0.5. The market value of their outstanding shares is at $297.7 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock rose 15.81% to $2.49. The market value of their outstanding shares is at $28.6 million. </li>
<li>Cadrenal Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVKD#NASDAQ">CVKD</a>) stock rose 13.62% to $13.18. The company's market cap stands at $21.8 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares rose 13.33% to $3.91. The company's market cap stands at $3.7 million. </li>
<li>Barinthus Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) stock moved upwards by 12.82% to $0.93. The market value of their outstanding shares is at $36.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Repare Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) stock decreased by 41.0% to $2.34 during Friday's pre-market session. The market value of their outstanding shares is at $99.5 million. </li>
<li>Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) shares declined by 32.48% to $2.54. The company's market cap stands at $66.2 million. </li>
<li>Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) stock fell 30.62% to $6.8. The market value of their outstanding shares is at $220.8 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) shares fell 20.84% to $0.19. The company's market cap stands at $20.5 million. </li>
<li>Bicycle Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCYC#NASDAQ">BCYC</a>) stock declined by 15.77% to $16.94. The company's market cap stands at $1.1 billion. </li>
<li>Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) shares decreased by 14.15% to $2.19. The market value of their outstanding shares is at $431.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BCYC

BRNS

CADL

CVKD

ESPR

ISPC

LTRN

RPTX

SENS

12 Health Care Stocks Moving In Friday's Pre-Market Session

U.S. stocks traded mixed toward the end of trading, with the S&amp;P 500 edging lower on Friday.
The Dow traded down 0.14% to 43,851.19 while the NASDAQ rose 0.04% to 19,911.75. The S&amp;P 500 also fell, dropping, 0.04% to 6,048.90.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company">Jim Cramer Says This CEO &#8216;Built An Amazing Company,&#8217; Recommends Buying Netflix</a>
Leading and Lagging Sectors Information technology shares jumped by 0.3% on Friday.
In trading on Friday, materials shares fell by 1.1%.
Top Headline
U.S. import prices increased by 0.1% from the previous month in November. Export prices came in unchanged for November compared to a 1% gain in the previous month.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>WISeKey International Holding AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKEY#NASDAQ">WKEY</a>) shares shot up 86% to $6.09 following the company's confirmation of its subsidiary WISeSat.Space's satellite launch with SpaceX. The goal of the launch is to deploy post-quantum-ready next-generation WISeSat satellites. This will showcase the combination of WISeKey's Root of Trust and SEALSQ's Post-Quantum Chips, providing security against emerging quantum threats.</li>
<li>Shares of Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) got a boost, surging 22% to $220.24 after the company posted better-than-expected earnings for its fourth quarter.</li>
<li>RH &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) shares were also up, gaining 13% to $430.78 after the company raised its guidance. Also, Baird maintained a Neutral rating on the stock and raised its price target from $300 to $400.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Repare Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) shares dropped 57% to $1.6895 after the company reported results of Lunresertib and Camonsertib combination from MYTHIC Phase 1 gynecologic expansion clinical trial.</li>
<li>Shares of 22nd Century Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) were down 35% to $0.0480 after the company announced a 1-for-135 reverse stock split.</li>
<li>Inovio Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) was down, falling 38% to $2.34 after the company announced a public offering of 10 million shares for gross proceeds of $30 million.</li>
</ul>
Commodities In commodity news, oil traded up 1.8% to $71.25 while gold traded down 1.3% at $2,675.00.
Silver traded down 1.8% to $31.050 on Friday, while copper fell 1.1% to $4.1985.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 fell 0.53%, Germany's DAX fell 0.10% and France's CAC 40 fell 0.15%. Spain's IBEX 35 Index slipped 0.11%, while London's FTSE 100 fell 0.14%.
Asia Pacific Markets
Asian markets closed mostly lower on Friday, with Japan's Nikkei 225 falling 0.95%, Hong Kong's Hang Seng Index dipping 2.09%, China's Shanghai Composite Index tumbling 2.01% and India's BSE Sensex gaining 1.04%.
Economics
<ul>
<li>U.S. import prices increased by 0.1% from the previous month in November.</li>
<li>U.S. export prices came in unchanged for November compared to a 1% gain in the previous month.</li>
<li>The total number of active U.S. oil rigs came in unchanged at 482 rigs this week, Baker Hughes Inc reported.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42483544/how-to-earn-500-a-month-from-meta-stock">How To Earn $500 A Month From Meta Stock</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

AVGO

WKEY

XXII

Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet

U.S. stocks traded lower midway through trading, with the Nasdaq Composite down around 0.2% on Friday.
The Dow traded down 0.20% to 43,824.10 while the NASDAQ fell 0.17% to 19,869.43. The S&amp;P 500 also fell, dropping, 0.14% to 6,042.84.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company">Jim Cramer Says This CEO &#8216;Built An Amazing Company,&#8217; Recommends Buying Netflix</a>
Leading and Lagging Sectors Utilities shares jumped by 0.3% on Friday.
In trading on Friday, communication services shares fell by 0.8%.
Top Headline
Shares of RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) rose around 15% on Friday after the company released quarterly results.
RH posted downbeat earnings and sales results for its third quarter. However, the company raised revenue guidance across the board based on current trends. The company expects fourth-quarter demand growth of 20% to 22%, and fourth-quarter revenue growth of 18% to 20%, according to data from Benzinga Pro.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>WISeKey International Holding AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKEY#NASDAQ">WKEY</a>) shares shot up 97% to $6.46. WISeKey announced WISeSat satellite launch with SpaceX on Jan. 14, 2025.</li>
<li>Shares of Loop Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOOP#NASDAQ">LOOP</a>) got a boost, surging 38% to $1.7020. Loop Industries completed convertible preferred financing with Reed Societe Generale Group.</li>
<li>SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) shares were also up, gaining 20% to $16.38.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Repare Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) shares dropped 50% to $1.9987 after the company reported results of Lunresertib and Camonsertib combination from MYTHIC Phase 1 gynecologic expansion clinical trial.</li>
<li>Shares of 22nd Century Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) were down 37% to $0.0461 after the company announced a 1-for-135 reverse stock split.</li>
<li>Inovio Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) was down, falling 41% to $2.2350 after the company announced a public offering of 10 million shares for gross proceeds of $30 million.</li>
</ul>
Commodities In commodity news, oil traded up 1.4% to $70.97 while gold traded down 1% at $2,682.30.
Silver traded down 2% to $30.985 on Friday, while copper fell 1.2% to $4.1940.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 fell 0.53%, Germany's DAX fell 0.10% and France's CAC 40 fell 0.15%. Spain's IBEX 35 Index slipped 0.11%, while London's FTSE 100 fell 0.14%.
Asia Pacific Markets
Asian markets closed mostly lower on Friday, with Japan's Nikkei 225 falling 0.95%, Hong Kong's Hang Seng Index dipping 2.09%, China's Shanghai Composite Index tumbling 2.01% and India's BSE Sensex gaining 1.04%.
Economics
<ul>
<li>U.S. import prices increased by 0.1% from the previous month in November.</li>
<li>U.S. export prices came in unchanged for November compared to a 1% gain in the previous month.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42483544/how-to-earn-500-a-month-from-meta-stock">How To Earn $500 A Month From Meta Stock</a></li>
</ul>

LOOP

SOUN

Crude Oil Gains Over 1%; RH Shares Jump On Strong Forecast

U.S. stocks traded mixed this morning, with the Dow Jones index down around 0.1% on Friday.
Following the market opening Friday, the Dow traded down 0.09% to 43,874.75 while the NASDAQ rose 0.42% to 19,987.05. The S&amp;P 500 also rose, gaining, 0.14% to 6,059.64.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company">Jim Cramer Says This CEO &#8216;Built An Amazing Company,&#8217; Recommends Buying Netflix</a>
Leading and Lagging Sectors Information technology shares jumped by 1% on Friday.
In trading on Friday, materials shares fell by 1.1%.
Top Headline
Shares of Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) jumped around 22% on Friday after the company posted better-than-expected earnings for its fourth quarter.
The company said it sees first-quarter revenue of approximately $14.6 billion, versus the $14.612 billion estimate. The company also issued adjusted EBITDA guidance of approximately 66 percent of projected revenue for the first quarter.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>WISeKey International Holding AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKEY#NASDAQ">WKEY</a>) shares shot up 75% to $5.74. WISeKey announced WISeSat satellite launch with SpaceX on Jan. 14, 2025.</li>
<li>Shares of Loop Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOOP#NASDAQ">LOOP</a>) got a boost, surging 35% to $1.6693. Loop Industries completed convertible preferred financing with Reed Societe Generale Group.</li>
<li>TruGolf Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>) shares were also up, gaining 35% to $0.7034 after jumping around 18% on Thursday.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Repare Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) shares dropped 48% to $2.08 after the company reported results of Lunresertib and Camonsertib combination from MYTHIC Phase 1 gynecologic expansion clinical trial.</li>
<li>Shares of 22nd Century Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) were down 42% to $0.0425 after the company announced a 1-for-135 reverse stock split.</li>
<li>Inovio Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) was down, falling 40% to $2.2701 after the company announced a public offering of 10 million shares for gross proceeds of $30 million.</li>
</ul>
Commodities In commodity news, oil traded up 0.9% to $70.65 while gold traded down 1.2% at $2,676.40.
Silver traded down 2.5% to $30.830 on Friday, while copper fell 1.2% to $4.1950.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.55%, Germany's DAX fell 0.15% and France's CAC 40 fell 0.18%. Spain's IBEX 35 Index slipped 0.14%, while London's FTSE 100 fell 0.33%.
Asia Pacific Markets
Asian markets closed mostly lower on Friday, with Japan's Nikkei 225 falling 0.95%, Hong Kong's Hang Seng Index dipping 2.09%, China's Shanghai Composite Index tumbling 2.01% and India's BSE Sensex gaining 1.04%.
Economics
<ul>
<li>U.S. import prices increased by 0.1% from the previous month in November.</li>
<li>U.S. export prices came in unchanged for November compared to a 1% gain in the previous month.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42483544/how-to-earn-500-a-month-from-meta-stock">How To Earn $500 A Month From Meta Stock</a></li>
</ul>

TRUG

US Stocks Mixed; Broadcom Shares Surge On Upbeat Earnings

Offerings

Press Releases

INOVIO Announces Proposed Public Offering

INOVIO Announces Pricing of $30 Million Public Offering

INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments

INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference

Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025

INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19

INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Comments

Inovio Pharmaceuticals

Inovio Pharmaceuticals (INO) Opzioni

Inovio Pharmaceuticals (NASDAQ:INO) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO